STUDY OBJECTIVES: To evaluate the use of sham-continuous positive airway pressure (CPAP) treatment as a placebo intervention. DESIGN AND SETTING: Analysis of polysomnograms performed in fixed order without sham-CPAP and on the first night of the sham-CPAP intervention in participants in the CPAP Apnea Trial North American Program (CATNAP), a randomized, placebo controlled trial evaluating the effects of CPAP treatment on daytime function in adults with newly diagnosed mild to moderate obstructive sleep apnea (apnea hypopnea index (AHI) 5-30). PARTICIPANTS: The first 104 CATNAP participants randomized to the sham-CPAP intervention arm. MEASUREMENTS AND RESULTS: Compared to the polysomnographic measures without sham-CPAP, the study on the first night with sham-CPAP had statistically significant differences that suggested a decrease in sleep quality: decreased sleep efficiency, increased arousal index, increased time in stage 1 NREM sleep, and prolonged latency to REM sleep. However, all of these differences had a relatively small effect size. Compared to the polysomnogram without sham-CPAP, the number of hypopneas on the sham-CPAP polysomnogram was significantly increased and the number of apneas significantly decreased. Relatively minor differences in AHI with and without sham-CPAP were present and were dependent on the criteria used to score hypopneas. CONCLUSION: Comparison of polysomnograms with and without sham-CPAP revealed differences that, although statistically significant, were small in magnitude and had relatively low effect sizes suggesting minimal clinical significance. The results support the use of sham-CPAP as a placebo intervention in trials evaluating the effects of CPAP treatment in patients with obstructive sleep apnea. CLINICAL TRIAL INFORMATION: This paper was a secondary analysis of clinical trial data. CATNAP: CPAP Apnea Trial North American Program, the trial from which the data were obtained, is registered with clinicaltrial.gov. Registration #NCT00089752.
RCT Entities:
STUDY OBJECTIVES: To evaluate the use of sham-continuous positive airway pressure (CPAP) treatment as a placebo intervention. DESIGN AND SETTING: Analysis of polysomnograms performed in fixed order without sham-CPAP and on the first night of the sham-CPAP intervention in participants in the CPAPApnea Trial North American Program (CATNAP), a randomized, placebo controlled trial evaluating the effects of CPAP treatment on daytime function in adults with newly diagnosed mild to moderate obstructive sleep apnea (apnea hypopnea index (AHI) 5-30). PARTICIPANTS: The first 104 CATNAP participants randomized to the sham-CPAP intervention arm. MEASUREMENTS AND RESULTS: Compared to the polysomnographic measures without sham-CPAP, the study on the first night with sham-CPAP had statistically significant differences that suggested a decrease in sleep quality: decreased sleep efficiency, increased arousal index, increased time in stage 1 NREM sleep, and prolonged latency to REM sleep. However, all of these differences had a relatively small effect size. Compared to the polysomnogram without sham-CPAP, the number of hypopneas on the sham-CPAP polysomnogram was significantly increased and the number of apneas significantly decreased. Relatively minor differences in AHI with and without sham-CPAP were present and were dependent on the criteria used to score hypopneas. CONCLUSION: Comparison of polysomnograms with and without sham-CPAP revealed differences that, although statistically significant, were small in magnitude and had relatively low effect sizes suggesting minimal clinical significance. The results support the use of sham-CPAP as a placebo intervention in trials evaluating the effects of CPAP treatment in patients with obstructive sleep apnea. CLINICAL TRIAL INFORMATION: This paper was a secondary analysis of clinical trial data. CATNAP: CPAPApnea Trial North American Program, the trial from which the data were obtained, is registered with clinicaltrial.gov. Registration #NCT00089752.
Authors: O Le Bon; L Staner; G Hoffmann; M Dramaix; I San Sebastian; J R Murphy; M Kentos; I Pelc; P Linkowski Journal: J Psychiatr Res Date: 2001 May-Jun Impact factor: 4.791
Authors: T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda Journal: Psychiatry Clin Neurosci Date: 2001-06 Impact factor: 5.188
Authors: Maree Barnes; Danielle Houston; Christopher J Worsnop; Alister M Neill; Ivanka J Mykytyn; Amanda Kay; John Trinder; Nicholas A Saunders; R Douglas McEvoy; Robert J Pierce Journal: Am J Respir Crit Care Med Date: 2002-03-15 Impact factor: 21.405
Authors: Eileen R Chasens; Charles W Atwood; Lora E Burke; Mary Korytkowski; Robert Stansbury; Patrick J Strollo; Susan M Sereika Journal: Contemp Clin Trials Date: 2018-12-02 Impact factor: 2.226
Authors: Janet T Holbrook; Elizabeth A Sugar; Robert H Brown; Lea T Drye; Charles G Irvin; Alan R Schwartz; Robert S Tepper; Robert A Wise; Razan Z Yasin; Michael F Busk Journal: Ann Am Thorac Soc Date: 2016-11
Authors: Devin L Brown; Craig S Anderson; Ronald D Chervin; Clete A Kushida; Daniel S Lewin; Beth A Malow; Susan Redline; Edward B Goldman Journal: J Clin Sleep Med Date: 2011-02-15 Impact factor: 4.062
Authors: Michelle L Reid; Kevin J Gleason; Jessie P Bakker; Rui Wang; Murray A Mittleman; Susan Redline Journal: Sleep Date: 2019-08-01 Impact factor: 5.849
Authors: Babak Mokhlesi; Daniela Grimaldi; Guglielmo Beccuti; Varghese Abraham; Harry Whitmore; Fanny Delebecque; Eve Van Cauter Journal: Am J Respir Crit Care Med Date: 2016-08-15 Impact factor: 21.405
Authors: Sushmita Pamidi; Kristen Wroblewski; Magdalena Stepien; Khalid Sharif-Sidi; Jennifer Kilkus; Harry Whitmore; Esra Tasali Journal: Am J Respir Crit Care Med Date: 2015-07-01 Impact factor: 21.405